BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DT120 (Lysergide tartrate (LSD)) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of DT120 (Lysergide tartrate (LSD))\, from C
 linicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07592689-827@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:DT120 (Lysergide tartrate (LSD)): Phase 3 readout est. (NCT07592689
 )
DESCRIPTION:DT120 (Lysergide tartrate (LSD))\, phase 3\, Major Depressive D
 isorder.\nStudy: A Phase 3 Trial of DT120 for Major Depressive Disorder (A
 scend)\nEstimated primary completion: September 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/lysergide-tartrate-lsd#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07592689
URL:https://assetmemo.bio/drug/lysergide-tartrate-lsd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
